Compare Magnolia Oil & Gas Corporation Class A Common Stock (MGY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magnolia Oil & Gas Corporation Class A Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.9 (market cap $6.76B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Magnolia Oil & Gas Corporation Class A Common Stock and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Magnolia Oil & Gas Corporation Class A Common Stock pays a 2.63% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MGY | SYRE | |
|---|---|---|
Market Cap | $6.76B | $7.52B |
Volume | 2,815,157 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $32.36 | $108.92 |
52-Week Low | $21.24 | $22.18 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.88B | $6.52B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Magnolia Oil & Gas Corporation Class A Common Stock
Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
